CO2021015432A2 - Secuencia promotora y productos y usos relacionados de la misma - Google Patents

Secuencia promotora y productos y usos relacionados de la misma

Info

Publication number
CO2021015432A2
CO2021015432A2 CONC2021/0015432A CO2021015432A CO2021015432A2 CO 2021015432 A2 CO2021015432 A2 CO 2021015432A2 CO 2021015432 A CO2021015432 A CO 2021015432A CO 2021015432 A2 CO2021015432 A2 CO 2021015432A2
Authority
CO
Colombia
Prior art keywords
disclosed
promoter sequence
related products
gene expression
promoters
Prior art date
Application number
CONC2021/0015432A
Other languages
English (en)
Inventor
Markus Grompe
Sunghee Chai
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of CO2021015432A2 publication Critical patent/CO2021015432A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona elementos promotores cortos ubicuos capaces de impulsar la expresión génica en múltiples tipos de células de mamíferos de interés médico. Los vectores de expresión que incorporan los promotores se divulgan en el presente documento. En el presente documento se divulgan vectores víricos, en particular, vectores AAV con capacidad para transgenes más grandes que los que son posibles con los promotores convencionales. En el presente documento se divulgan métodos para potenciar la expresión génica
CONC2021/0015432A 2019-04-24 2021-11-17 Secuencia promotora y productos y usos relacionados de la misma CO2021015432A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838063P 2019-04-24 2019-04-24
PCT/US2020/029918 WO2020219949A1 (en) 2019-04-24 2020-04-24 Promoter sequence and related products and uses thereof

Publications (1)

Publication Number Publication Date
CO2021015432A2 true CO2021015432A2 (es) 2021-11-19

Family

ID=72941869

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015432A CO2021015432A2 (es) 2019-04-24 2021-11-17 Secuencia promotora y productos y usos relacionados de la misma

Country Status (15)

Country Link
US (1) US20220204988A1 (es)
EP (1) EP3958912A4 (es)
JP (1) JP2022529771A (es)
KR (1) KR20220003520A (es)
CN (1) CN113727735A (es)
AU (1) AU2020263573A1 (es)
BR (1) BR112021020311A2 (es)
CA (1) CA3136460A1 (es)
CL (1) CL2021002577A1 (es)
CO (1) CO2021015432A2 (es)
IL (1) IL287386A (es)
MX (1) MX2021012578A (es)
PE (1) PE20212082A1 (es)
SG (1) SG11202110926XA (es)
WO (1) WO2020219949A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031640A (zh) * 2004-07-29 2007-09-05 干细胞创新有限公司 干细胞的分化
EP3456331B1 (en) * 2006-02-08 2021-05-26 Genzyme Corporation Gene therapy for niemann-pick disease type a
BR112013025819A2 (pt) * 2011-04-07 2016-12-20 Bayer Crospscience N V promotor específico para semente em algodão
CA3221516A1 (en) * 2013-08-22 2015-02-26 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
US10378055B2 (en) * 2015-04-08 2019-08-13 City Of Hope Methods and compositions for measuring beta cell death
US11390866B2 (en) * 2015-12-04 2022-07-19 Sorbonne Université Promoters and uses thereof

Also Published As

Publication number Publication date
AU2020263573A1 (en) 2021-10-28
US20220204988A1 (en) 2022-06-30
PE20212082A1 (es) 2021-10-28
MX2021012578A (es) 2021-12-10
CN113727735A (zh) 2021-11-30
CL2021002577A1 (es) 2022-09-09
SG11202110926XA (en) 2021-11-29
EP3958912A1 (en) 2022-03-02
IL287386A (en) 2021-12-01
JP2022529771A (ja) 2022-06-24
EP3958912A4 (en) 2023-02-22
BR112021020311A2 (pt) 2021-12-14
KR20220003520A (ko) 2022-01-10
WO2020219949A1 (en) 2020-10-29
CA3136460A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
BR112019010565A2 (pt) aplicação viral de neoantígenos
BR112017027869A2 (pt) degrons dependentes de maltose, promotores responsivos à maltose, construtos de estabilização, e seu uso na produção de compostos não catabólicos
CO2017009083A2 (es) Arni dirigido a la proteína hungtingtina, partículas víricas que lo contienen y métodos para reducir la toxicicidad del arni
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
PE20181275A1 (es) Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo
CO2018006699A2 (es) Métodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspensión sin suero adecuado para uso clínico
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
CL2016002840A1 (es) Composiciones que comprenden aav que expresa constructos de anticuerpos duales y sus usos
UY37970A (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
CO2019014683A2 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas
AR100705A1 (es) Vector de expresión t7 de escherichia coli, vectores para la coexpresión y copurificación de polipéptidos recombinantes en / con proteínas cargadoras, uso de vectores de expresión en la obtención de complejos con múltiples antígenos e inmunomoduladores
MX2020005282A (es) Vector para la produccion de particulas aav.
AR101057A1 (es) Composiciones y métodos que comprenden una variante de la enzima xilanasa
BR112015021785A2 (pt) Promotores de levedura para expressão de proteína
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
WO2019226939A8 (en) Immune checkpoint inhibitor co-expression vectors
CO2021015432A2 (es) Secuencia promotora y productos y usos relacionados de la misma
BR112014031526A2 (pt) promotores para expressar um gene em uma célula
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
AR110908A1 (es) Constructo promotor para la síntesis de proteínas libre de células
BR112018005464A2 (pt) expressão de proteínas contendo fc
AR113124A1 (es) Sistema de expresión de paramyxoviridae
MX2023007527A (es) Metodos y sistemas para transfeccion celular mejorada.
BR112015023263A2 (pt) clonagem e uso do gene ms9 do milho